Clinical trial
A Prospective, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne (Study FX2016 40)
NCT04104685 is registered in ClinicalTrials.gov with Vyne Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne (Study FX2016 40)
- Lead sponsor
- Vyne Therapeutics Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 18, 2019
- Completion date
- March 3, 2020
- Enrollment
- 446 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.